|
[1]
|
Gupta, A. and Madke, B. (2022) Psoriasis a Cause of Cardiovascular Diseases: A Review Article. Cureus, 14, e27767. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Martinez-Moreno, A., Ocampo-Candiani, J. and Garza-Rodriguez, V. (2021) Psoriasis and Cardiovascular Disease: A Narrative Review. Korean Journal of Family Medicine, 42, 345-355. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Piaserico, S. and Messina, F. (2022) Pharmacological Management of Severe Plaque Psoriasis in Patients with Cardiovascular Disease. Expert Opinion on Pharmacotherapy, 23, 853-864. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Gonzalez‐Cantero, A., Boehncke, W.H., De Sutter, J., Zamorano, J.L., Lambert, J. and Puig, L. (2023) Statins and Psoriasis: Position Statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology. Journal of the European Academy of Dermatology and Venereology, 37, 1697-1705. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Näslund-Koch, C., Vedel-Krogh, S., Bojesen, S.E. and Skov, L. (2022) Traditional and Non-Traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis. Acta Dermato-Venereologica, 102, adv00789. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Andújar, I., Esplugues, J.V. and García-Martínez, P. (2022) Looking Beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. Pharmaceuticals, 15, Article 1101. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kommoss, K.S., Enk, A., Heikenwälder, M., Waisman, A., Karbach, S. and Wild, J. (2023) Cardiovascular Comorbidity in Psoriasis—Psoriatic Inflammation Is More than Just Skin Deep. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 21, 718-725. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Potestio, L., Tommasino, N., Lauletta, G., Martora, F. and Megna, M. (2024) Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and Therapy, 14, 841-852. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Kim, B.R., Lee, K.H., Paik, K., Kim, M., Bae, J.M., Choi, C.W., et al. (2024) Automated Mass Screening and Association Rules Analysis for Comorbidities of Psoriasis: A Population‐Based Case-Control Study. The Journal of Dermatology, 51, 539-551. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Riaz, S., Emam, S., Wang, T. and Gniadecki, R. (2024) Negative Impact of Comorbidities on All-Cause Mortality of Patients with Psoriasis Is Partially Alleviated by Biologic Treatment: A Real-World Case-Control Study. Journal of the American Academy of Dermatology, 91, 43-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Wang, Y., Zang, J., Liu, C., Yan, Z. and Shi, D. (2022) Interleukin-17 Links Inflammatory Cross-Talks between Comorbid Psoriasis and Atherosclerosis. Frontiers in Immunology, 13, Article 835671. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Gisondi, P., Bellinato, F., Girolomoni, G. and Albanesi, C. (2020) Pathogenesis of Chronic Plaque Psoriasis and Its Intersection with Cardio-Metabolic Comorbidities. Frontiers in Pharmacology, 11, Article 117. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Purzycka-Bohdan, D., Kisielnicka, A., Bohdan, M., Szczerkowska-Dobosz, A., Sobalska-Kwapis, M., Nedoszytko, B., et al. (2021) Analysis of the Potential Genetic Links between Psoriasis and Cardiovascular Risk Factors. International Journal of Molecular Sciences, 22, Article 9063. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Terui, H. and Asano, Y. (2023) Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. Journal of Clinical Medicine, 12, Article 1162. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Piaserico, S., Orlando, G. and Messina, F. (2022) Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. International Journal of Molecular Sciences, 23, Article 9063. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Elfaki, I., Mir, R., Elnageeb, M.E., Hamadi, A., Alharbi, Z.M., Bedaiwi, R.I., et al. (2025) Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome—An Update. Medicina, 61, Article 83. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Succurro, E., Vizza, P., Papa, A., Cicone, F., Monea, G., Tradigo, G., et al. (2022) Metabolic Syndrome Is Associated with Impaired Insulin-Stimulated Myocardial Glucose Metabolic Rate in Individuals with Type 2 Diabetes: A Cardiac Dynamic 18F-FDG-PET Study. Frontiers in Cardiovascular Medicine, 9, Article 924787. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Mosca, M., Hong, J., Hadeler, E., Hakimi, M., Brownstone, N., Liao, W., et al. (2021) Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials. Dermatology and Therapy, 11, 1497-1520. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Xie, L., Fefelova, N., Pamarthi, S.H. and Gwathmey, J.K. (2022) Molecular Mechanisms of Ferroptosis and Relevance to Cardiovascular Disease. Cells, 11, Article 2726. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Huang, R., Zhao, S., Li, Y., Liu, F., Gong, Y., Xing, J., et al. (2020) Association of Tumor Necrosis Factor-Α Gene Polymorphisms and Coronary Artery Disease Susceptibility: A Systematic Review and Meta-Analysis. BMC Medical Genetics, 21, Article No. 29. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Wang, L. and Zhou, H. (2019) A Meta-Analysis of the Relationship between Tumor Necrosis Factor-α Polymorphisms and Psoriasis. Dermatology, 237, 39-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Wu, Y., Huang, M., Chen, X., Wu, J., Li, L., Wei, J., et al. (2024) A Genome-Wide Cross-Trait Analysis Identifies Shared Loci and Causal Relationships of Obesity and Lipidemic Traits with Psoriasis. Frontiers in Immunology, 15, Article 1328297. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Orcales, F., Kumar, S., Bui, A., Johnson, C., Liu, J., Huang, Z., et al. (2024) A Partitioned Polygenic Risk Score Reveals Distinct Contributions to Psoriasis Clinical Phenotypes across a Multi-Ethnic Cohort. Journal of Translational Medicine, 22, Article No. 835. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Garshick, M.S., Vaidean, G., Nikain, C.A., Chen, Y., Smilowitz, N.R. and Berger, J.S. (2019) Sex Differences in the Prevalence of Vascular Disease and Risk Factors in Young Hospitalized Patients with Psoriasis. International Journal of Women’s Dermatology, 5, 251-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Masson, W., Lobo, M. and Molinero, G. (2020) Psoriasis and Cardiovascular Risk: A Comprehensive Review. Advances in Therapy, 37, 2017-2033. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Liu, L., Cui, S., Liu, M., Huo, X., Zhang, G. and Wang, N. (2022) Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Frontiers in Cardiovascular Medicine, 9, Article 829709. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Kleyn, C., Talbot, P., Mehta, N., Sampogna, F., Bundy, C., Ashcroft, D., et al. (2020) Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk. Acta Dermato Venereologica, 100, 1-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Muthalaly, R.G., Nelson, A.J., Baradi, A., Mehta, O.H., Wilson, A.M. and Nasis, A. (2023) Socioeconomic Determinants of Health, Traditional Risk Factors and Cardiovascular Outcomes in Australia. International Journal of Cardiology Cardiovascular Risk and Prevention, 17, Article ID: 200184. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Eckembrecher, D.G., Eckembrecher, F.J., Patel, S., Hombal, A., Hernandez, L. and Nouri, K. (2024) A Cross-Sectional Study of Psoriasis Hospitalizations in Patients with Cardiovascular Comorbidities in Patients under 60. Archives of Dermatological Research, 316, Article No. 322. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Northcott, M., Gearing, L.J., Nim, H.T., Nataraja, C., Hertzog, P., Jones, S.A., et al. (2021) Glucocorticoid Gene Signatures in Systemic Lupus Erythematosus and the Effects of Type I Interferon: A Cross-Sectional and In-Vitro Study. The Lancet Rheumatology, 3, e357-e370. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Spinelli, E. and Werner Junior, J. (2022) Human Adaptative Behavior to Antarctic Conditions: A Review of Physiological Aspects. WIREs Mechanisms of Disease, 14, e1556. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Choi, H., Uceda, D.E., Dey, A.K., Abdelrahman, K.M., Aksentijevich, M., Rodante, J.A., et al. (2020) Treatment of Psoriasis with Biologic Therapy Is Associated with Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core. Circulation: Cardiovascular Imaging, 13, e011199. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Ni, R., Zheng, J., Varghese, J. and Kumar, B. (2024) The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus, 16, e60980. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Chhotaray, S. and Jal, S. (2025) Identifying Biomarkers for Atherosclerosis via Gene Expression and Biological Networking. Current Cardiology Reviews, 21, e1573403X340118. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Zhang, C., Lei, S., Ma, A., Wang, B., Wang, S., Liu, J., et al. (2024) Evaluation of Tumor Microvasculature with 3D Ultrasound Localization Microscopy Based on 2D Matrix Array. European Radiology, 34, 5250-5259. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Elmets, C.A., Leonardi, C.L., Davis, D.M.R., et al. (2019) Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Awareness and Attention to Comorbidities. Journal of the American Academy of Dermatology, 80, 1073-1113.
|
|
[37]
|
Lambert, J.L.W., Segaert, S., Ghislain, P.D., Hillary, T., Nikkels, A., Willaert, F., et al. (2020) Practical Recommendations for Systemic Treatment in Psoriasis According to Age, Pregnancy, Metabolic Syndrome, Mental Health, Psoriasis Subtype and Treatment History (BETA‐PSO: Belgian Evidence‐Based Treatment Advice in Psoriasis; Part 1). Journal of the European Academy of Dermatology and Venereology, 34, 1654-1665. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Hu, S. and Lan, C.E. (2017) Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. International Journal of Molecular Sciences, 18, Article 2211. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Hachemi, Y., Rapp, A.E., Lee, S., Dorn, A., Krüger, B.T., Kaiser, K., et al. (2021) Intact Glucocorticoid Receptor Dimerization Is Deleterious in Trauma-Induced Impaired Fracture Healing. Frontiers in Immunology, 11, Article 628287. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Kim, S., Jensen, A., Egeberg, A. and Stensballe, L.G. (2024) Post‐Marketing Safety of Ustekinumab Based on 14‐Year Follow‐Up in Danish National Patient Data. Pharmacoepidemiology and Drug Safety, 33, e70064. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Hughes, D.M., Yiu, Z.Z.N. and Zhao, S.S. (2025) External Validation of the Accuracy of Cardiovascular Risk Prediction Tools in Psoriatic Disease: A UK Biobank Study. Clinical Rheumatology, 44, 1151-1161. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Kampe, T., Baloghová, J., Kolarčik, P., Rimárová, K. and Dorko, E. (2024) SCORE2 Screening Tool for Cardiovascular Risk Assessment in Psoriasis—A Case–Control Study. Journal of Clinical Medicine, 13, Article 3237. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Dey, A.K., Teague, H.L., Adamstein, N.H., Rodante, J.A., Playford, M.P., Chen, M.Y., et al. (2021) Association of Neutrophil-To-Lymphocyte Ratio with Non-Calcified Coronary Artery Burden in Psoriasis: Findings from an Observational Cohort Study. Journal of Cardiovascular Computed Tomography, 15, 372-379. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Walton, R.M. and Siegel, A. (2022) Avian Inflammatory Markers. Veterinary Clinics of North America: Exotic Animal Practice, 25, 679-695. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Anyfanti, P., Margouta, A., Goulas, K., Gavriilaki, M., Lazaridou, E., Patsatsi, A., et al. (2022) Endothelial Dysfunction in Psoriasis: An Updated Review. Frontiers in Medicine, 9, Article 864185. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Roshan, A., Choo, J. and Lim, C. (2022) Readability, Understandability, and Actionability of Online Cardiovascular Risk Assessment Tools and Patient Educational Material: A Systematic Review. Glomerular Diseases, 3, 56-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Ismail, A.M.A. and Hamed, D.E. (2023) Erectile Dysfunction and Metabolic Syndrome Components in Obese Men with Psoriasis: Response to a 12-Week Randomized Controlled Lifestyle Modification Program (Exercise with Diet Restriction). Irish Journal of Medical Science (1971-), 193, 523-529. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
DE Luca, D.A., Papara, C., Hawro, T. and Thaçi, D. (2025) Psoriasis and Diabetes: A Review of the Pathophysiological and Therapeutic Interconnections. Minerva Medica, 116, 195-222. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Dodulík, J., Dodulíková, L., Plášek, J., Ramík, Z., Vrtal, J. and Václavík, J. (2025) Pharmacotherapy of Arterial Hypertension in Patients withPsoriasis. Journal of Hypertension, 43, 568-576. [Google Scholar] [CrossRef] [PubMed]
|